Dr. Steven Rosenberg, PhD, FAHA is an innovative scientific entrepreneur who is a 35 year veteran of the Biotechnology industry. Dr. Rosenberg is a member of a number of advisory boards including CardioDx, as well as the Board of Directors of KMT Hepatech, and a consultant to other companies. He has particular recent experience in molecular diagnostics in oncology, immunology, and cardiovascular diseases. Most recently he served as Chief Scientific Officer at Cardiodx (2006-2014) and prior to that in the same position at XDx (now CareDx, NASDAQ, CDNA) (2003-2006). He led the research and development activities, resulting in the validation, launch, and commercialization of two blood-based genomic diagnostics (AlloMap, for heart transplant, FDA cleared) and Corus CAD for coronary artery disease.
From 2001-2003 he was a visiting scholar and lecturer at the University of California, Berkeley, Department of Chemistry, and a consultant to a variety of biotechnology companies, including Genomic Health (NASDAQ GHDX), Syrrx, and Signature Biosciences. Prior to that he spent 20 years at Chiron Corporation from the company’s inception (as employee #13) in 1981. He rose to become one of 3 Chiron Research Fellows, with responsibilities in small molecular drug discovery, computational chemistry, biochemistry, infectious disease, and oncology. Earlier in his career at Chiron he was a member of the team that developed the first recombinant DNA-based vaccine for Hepatitis B, now in world-wide use.
He has published more than 60 scientific papers and is an inventor on more than 30 US patents. He is a member of the AHA, ACS, and AAAS. Steve received his BA cum laude in Chemistry from Brandeis University where he worked with William P. Jencks in the Biochemistry Department. He then obtained his PhD in Biochemistry in 1978 from the University of California, Berkeley and was an American Cancer Society post-doctoral fellow at Berkeley until he joined Chiron.